The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.
Copaxone is a prescription drug used to treat different types of multiple sclerosis (MS) in adults. It can cause side effects that range from mild to serious, including injection site reactions, ...
Copaxone is available in two strengths: 20 milligrams (mg) per 1 milliliter (mL) of liquid solution and 40 mg/mL. The drug comes in single-dose prefilled syringes for injection under the skin. For all ...
Approved in 1996, Copaxone® is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS) Ongoing, prospective, clinical trial follow-up reinforces the established ...
Additional Preclinical Data to be Presented at the Fifth Joint Triennial Congress of ECTRIMS and ACTRIMS Further Elucidate the Anti-inflammatory Mechanism of COPAXONE® JERUSALEM--(BUSINESS WIRE)-- ...
JERUSALEM--(BUSINESS WIRE)--Sep. 28, 2015-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) announced today the approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) of ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. COPAXONE PEN contains the active ingredient glatiramer acetate.
JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced positive results from a study assessing a new lower-volume injection of Copaxone ® (glatiramer acetate) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback